A szomatosztatinanalóg kezelés eredményei acromegaliában

Translated title of the contribution: Outcome of somatostatin analogue treatment in acromegaly

Mondok Ágnes, Tóth Miklós, A. Patócs, Szücs Nikolette, P. Igaz, Pusztai Péter, S. Czirják, G. Bekő, E. Gláz, K. Rácz, Z. Tulassay

Research output: Contribution to journalArticle

Abstract

During the past decade the importance of medical therapy, especially treatment with somatostatin analogues has increased significantly in patients with active acromegaly. Aims: Authors analyzed the outcome of somatostatin analogue treatment in acromegalic patients evaluated and followed up at the 2nd Department of Medicine, Faculty of Medicine, Semmelweis University, during the past 10 years. Patients and methods: Changes in serum growth hormone (GH) and insulin-like growth factor-1 (IGF-1) concentration, as well as morphologic changes of pituitary adenomas followed by MRI scans were evaluated and compared in 32 acromegalic patients (26 women, 6 men) during long-term somatostatin analogue treatment (mean±SE, 3.1±0.3 years, range, 1-7 years). Primary somatostatin analogue treatment was applied in 10 patients (7 women and 3 men), whereas 15 patients (14 women and 1 man) had pituitary surgery and 7 patients (5 women and 2 men) underwent both pituitary surgery and irradiation therapy prior to somatostatin analogue treatment. Results: After a 3-month treatment with somatostatin analogues, both serum GH and IGF-1 levels decreased significantly and they remained around the same decreased levels throughout the treatment period. Serum GH decreased from 15.7±4.9 to 5.5±1.4 ng/ml, and serum IGF-1, expressed as a percentage of the upper limit of age- and sex-adjusted reference value, decreased from 204±14% to 135±12% at the end of treatment. The efficacy of somatostatin analogue treatment was not influenced by surgical or surgical and irradiation therapies which were applied prior to medical treatment. At the end of treatment 36.7% of patients had safe serum GH (

Original languageHungarian
Pages (from-to)1457-1462
Number of pages6
JournalOrvosi Hetilap
Volume150
Issue number31
DOIs
Publication statusPublished - Aug 1 2009

Fingerprint

Acromegaly
Somatostatin
Therapeutics
Growth Hormone
Somatomedins
Serum
Pituitary Irradiation
Medicine
Pituitary Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A szomatosztatinanalóg kezelés eredményei acromegaliában. / Ágnes, Mondok; Miklós, Tóth; Patócs, A.; Nikolette, Szücs; Igaz, P.; Péter, Pusztai; Czirják, S.; Bekő, G.; Gláz, E.; Rácz, K.; Tulassay, Z.

In: Orvosi Hetilap, Vol. 150, No. 31, 01.08.2009, p. 1457-1462.

Research output: Contribution to journalArticle

Ágnes, Mondok ; Miklós, Tóth ; Patócs, A. ; Nikolette, Szücs ; Igaz, P. ; Péter, Pusztai ; Czirják, S. ; Bekő, G. ; Gláz, E. ; Rácz, K. ; Tulassay, Z. / A szomatosztatinanalóg kezelés eredményei acromegaliában. In: Orvosi Hetilap. 2009 ; Vol. 150, No. 31. pp. 1457-1462.
@article{ed965de907a642999e7343633f94d002,
title = "A szomatosztatinanal{\'o}g kezel{\'e}s eredm{\'e}nyei acromegali{\'a}ban",
abstract = "During the past decade the importance of medical therapy, especially treatment with somatostatin analogues has increased significantly in patients with active acromegaly. Aims: Authors analyzed the outcome of somatostatin analogue treatment in acromegalic patients evaluated and followed up at the 2nd Department of Medicine, Faculty of Medicine, Semmelweis University, during the past 10 years. Patients and methods: Changes in serum growth hormone (GH) and insulin-like growth factor-1 (IGF-1) concentration, as well as morphologic changes of pituitary adenomas followed by MRI scans were evaluated and compared in 32 acromegalic patients (26 women, 6 men) during long-term somatostatin analogue treatment (mean±SE, 3.1±0.3 years, range, 1-7 years). Primary somatostatin analogue treatment was applied in 10 patients (7 women and 3 men), whereas 15 patients (14 women and 1 man) had pituitary surgery and 7 patients (5 women and 2 men) underwent both pituitary surgery and irradiation therapy prior to somatostatin analogue treatment. Results: After a 3-month treatment with somatostatin analogues, both serum GH and IGF-1 levels decreased significantly and they remained around the same decreased levels throughout the treatment period. Serum GH decreased from 15.7±4.9 to 5.5±1.4 ng/ml, and serum IGF-1, expressed as a percentage of the upper limit of age- and sex-adjusted reference value, decreased from 204±14{\%} to 135±12{\%} at the end of treatment. The efficacy of somatostatin analogue treatment was not influenced by surgical or surgical and irradiation therapies which were applied prior to medical treatment. At the end of treatment 36.7{\%} of patients had safe serum GH (",
keywords = "Acromegaly, Growth hormone, Insulin-like growth factor-1, Pituitary adenoma, Somatostatin analogue",
author = "Mondok {\'A}gnes and T{\'o}th Mikl{\'o}s and A. Pat{\'o}cs and Sz{\"u}cs Nikolette and P. Igaz and Pusztai P{\'e}ter and S. Czirj{\'a}k and G. Bekő and E. Gl{\'a}z and K. R{\'a}cz and Z. Tulassay",
year = "2009",
month = "8",
day = "1",
doi = "10.1556/OH.2009.28688",
language = "Hungarian",
volume = "150",
pages = "1457--1462",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "31",

}

TY - JOUR

T1 - A szomatosztatinanalóg kezelés eredményei acromegaliában

AU - Ágnes, Mondok

AU - Miklós, Tóth

AU - Patócs, A.

AU - Nikolette, Szücs

AU - Igaz, P.

AU - Péter, Pusztai

AU - Czirják, S.

AU - Bekő, G.

AU - Gláz, E.

AU - Rácz, K.

AU - Tulassay, Z.

PY - 2009/8/1

Y1 - 2009/8/1

N2 - During the past decade the importance of medical therapy, especially treatment with somatostatin analogues has increased significantly in patients with active acromegaly. Aims: Authors analyzed the outcome of somatostatin analogue treatment in acromegalic patients evaluated and followed up at the 2nd Department of Medicine, Faculty of Medicine, Semmelweis University, during the past 10 years. Patients and methods: Changes in serum growth hormone (GH) and insulin-like growth factor-1 (IGF-1) concentration, as well as morphologic changes of pituitary adenomas followed by MRI scans were evaluated and compared in 32 acromegalic patients (26 women, 6 men) during long-term somatostatin analogue treatment (mean±SE, 3.1±0.3 years, range, 1-7 years). Primary somatostatin analogue treatment was applied in 10 patients (7 women and 3 men), whereas 15 patients (14 women and 1 man) had pituitary surgery and 7 patients (5 women and 2 men) underwent both pituitary surgery and irradiation therapy prior to somatostatin analogue treatment. Results: After a 3-month treatment with somatostatin analogues, both serum GH and IGF-1 levels decreased significantly and they remained around the same decreased levels throughout the treatment period. Serum GH decreased from 15.7±4.9 to 5.5±1.4 ng/ml, and serum IGF-1, expressed as a percentage of the upper limit of age- and sex-adjusted reference value, decreased from 204±14% to 135±12% at the end of treatment. The efficacy of somatostatin analogue treatment was not influenced by surgical or surgical and irradiation therapies which were applied prior to medical treatment. At the end of treatment 36.7% of patients had safe serum GH (

AB - During the past decade the importance of medical therapy, especially treatment with somatostatin analogues has increased significantly in patients with active acromegaly. Aims: Authors analyzed the outcome of somatostatin analogue treatment in acromegalic patients evaluated and followed up at the 2nd Department of Medicine, Faculty of Medicine, Semmelweis University, during the past 10 years. Patients and methods: Changes in serum growth hormone (GH) and insulin-like growth factor-1 (IGF-1) concentration, as well as morphologic changes of pituitary adenomas followed by MRI scans were evaluated and compared in 32 acromegalic patients (26 women, 6 men) during long-term somatostatin analogue treatment (mean±SE, 3.1±0.3 years, range, 1-7 years). Primary somatostatin analogue treatment was applied in 10 patients (7 women and 3 men), whereas 15 patients (14 women and 1 man) had pituitary surgery and 7 patients (5 women and 2 men) underwent both pituitary surgery and irradiation therapy prior to somatostatin analogue treatment. Results: After a 3-month treatment with somatostatin analogues, both serum GH and IGF-1 levels decreased significantly and they remained around the same decreased levels throughout the treatment period. Serum GH decreased from 15.7±4.9 to 5.5±1.4 ng/ml, and serum IGF-1, expressed as a percentage of the upper limit of age- and sex-adjusted reference value, decreased from 204±14% to 135±12% at the end of treatment. The efficacy of somatostatin analogue treatment was not influenced by surgical or surgical and irradiation therapies which were applied prior to medical treatment. At the end of treatment 36.7% of patients had safe serum GH (

KW - Acromegaly

KW - Growth hormone

KW - Insulin-like growth factor-1

KW - Pituitary adenoma

KW - Somatostatin analogue

UR - http://www.scopus.com/inward/record.url?scp=68549086990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68549086990&partnerID=8YFLogxK

U2 - 10.1556/OH.2009.28688

DO - 10.1556/OH.2009.28688

M3 - Article

C2 - 19617182

AN - SCOPUS:68549086990

VL - 150

SP - 1457

EP - 1462

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 31

ER -